Clinical trials: Hepatitis B Infections
Hepatitis C, Chronic
BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3
To assess the pharmacokenetic characteristics of 600 mg BID BI 207127 / 120 mg QD faldaprevir /ribavirin in a small number of GT1b HCV infected patients with mild hepatic impairment (CPA) (Arm 1) versus 400 mg BID BI 207127 / 120…
- Trial name
- NCT01830127
- Testing
- Ribavirin, BI 207127 high dose, Faldaprevir
- Where
- 19 sites in United States, Germany and 2 more
- Volunteers
- 35 people
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis B
An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine
An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine.
- Trial name
- NCT01264107
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Bukwang Pharmaceutical
Hepatitis B, Polio
Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV
The purpose of this study is to document the immunological response to the investigational hexavalent vaccine at the 6, 10, and 14 weeks schedule The primary objective is to demonstrate that the hexavalent DTaP-IPV-HB-PRP~T…
- Conditions
- Hepatitis B, Polio, Diphtheria, Pertussis
- Trial name
- NCT00362336
- Testing
- DTaP-IPV-HB-PRP~T, CombAct-HIB®, Engerix B® Pediatric
- Where
- 2 sites in South Africa
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy
Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine
The purpose of the study is to evaluate the safety, immunogenicity and lot-to-lot consistency of an investigational hepatitis B virus vaccine, HEPLISAV™, in healthy adults 40 to 70 years of age
- Trial name
- NCT01005407
- Testing
- Engerix-B
- Where
- 32 sites in United States, Canada
- Volunteers
- 2,452 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Hepatitis B
Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)
To evaluate the combination of telbivudine 600 mg orally (PO) once daily and peginterferon alpha-2a 180 ug subcutaneous (sq) injection weekly for antiviral efficacy in comparison to peginterferon alpha-2a monotherapy.
- Trial name
- NCT00412750
- Testing
- Telbivudine (LdT), peginterferon alpha-2a
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Novartis
Hepatitis B
Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children
This study will evaluate the persistence of immunity to hepatitis B in healthy children aged 7 to 8 years, after previous vaccination with Infanrix hexa™ in the first two years of life, and also their ability to mount an immune…
- Trial name
- NCT01333813
- Testing
- Engerix-B™ Kinder
- Where
- 12 sites in Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic, Chronic Hepatitis B
Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814
This is an open label, single-arm, multi-centre extension study for Korean patients with chronic hepatitis B and compensated liver disease who have completed one-year adefovir dipivoxil treatment in ADF103814.
- Trial name
- NCT00403585
- Testing
- adefovir dipivoxil 10mg
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Hepatitis B
Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)
This is a study to evaluate immunogenicity, safety, and tolerability of 2XP HEPTAVAX™-II compared with the 1XP HEPTAVAX™-II in healthy Japanese young adults.
- Trial name
- NCT01463683
- Testing
- 2XP HEPTAVAX™-II SC, 1XP HEPTAVAX™-II SC, 2XP HEPTAVAX™-II IM
- Volunteers
- 722 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
End Stage Renal Disease
Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis
The purpose of this study is to compare the immune response to HEPLISAV™ booster injection with the immune response to Engerix-B® and Fendrix® booster vaccinations among patients with end stage renal disease (ESRD) on…
- Trial name
- NCT01195246
- Testing
- HEPLISAV, Engerix-B, Fendrix
- Where
- 19 sites in Germany
- Volunteers
- 155 people
- Sponsor
- Dynavax Technologies Corporation
Chronic Hepatitis B
An Study of Efficacy and Safety of Clevudine
Randomized, double blind parallel group, positive control, multi-center trial. Patients will be randomized at 1:1 ratio in group A or group B
- Trial name
- NCT01192854
- Testing
- Clevudine, Adefovir
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Eisai Co., Ltd.
Chronic Hepatitis B
A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B
A multicenter, randomized, open, parallel-designed Phase II study to evaluate the efficacy and safety of HRS-5635 injection alone or in combination with other agents in patients treated for chronic hepatitis B.
- Trial name
- NCT06425341
- Testing
- HRS-5635 Injection, HRS-5635 Injection (low dose) and Peg-IFN-α, HRS-5635 Injection (high dose) and Peg-IFN-α
- Where
- China
- Volunteers
- 369 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Chronic Hepatitis B
Phase 3 and Extensional Study of Besifovir
To prove that a study drug is noninferior to a control drug with a proportion of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) at the 48th week after 48-week administration of Besifovir 150 mg, or…
- Trial name
- NCT01937806
- Testing
- besifovir 150mg, tenofovir 300mg
- Where
- 20 sites in South Korea
- Volunteers
- 197 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Chronic Hepatitis B
A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)
This is a study of sequential therapy with AHB-137 injection followed by TVAX-008 injection in participants living with Chronic Hepatitis B (CHB).
- Trial name
- NCT07897448
- Testing
- AHB-137, TVAX-008
- Volunteers
- 105 people
- Sponsor
- Grand Theravac Life Sciences (Hangzhou) Co., Ltd.
Chronic Hepatitis B
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
The primary objective of this study is to evaluate hepatitis B surface antigen (HBsAg) loss and seroconversion in participants who stop tenofovir disoproxil fumarate (TDF) (Stop TDF arm) compared to participants who continue TDF…
- Trial name
- FINITE CHB (NCT01320943)
- Testing
- TDF, Stop TDF
- Where
- 13 sites in Germany
- Volunteers
- 43 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B
This is an open-label study evaluating multiple doses of NCO-48 Fumarate versus tenofovir alafenamide (TAF).
- Trial name
- NCT04629976
- Testing
- NCO-48 Fumarate 4 mg, NCO-48 Fumarate 20 mg, Tenofovir Alafenamide 25 mg
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Nucorion Pharmaceuticals, Inc.
Hepatitis B Virus Infection
Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)
To describe the immunogenicity and safety of modified process hepatitis B vaccine administered to renal predialysis and dialysis patients
- Trial name
- NCT00440297
- Testing
- Comparator: modified process hepatitis B vaccine, Comparator: ENGERIX-B™
- Volunteers
- 277 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis B Virus Infection
A Study of HT-101 and HT-102 in Chronic Hepatitis B (CHB)
Phase II trial of HT-101 + HT-102 in CHB: (1) functional cure in treatment-naïve patients (vs placebo); (2) efficacy of sequential interferon in previously treated patients.
- Trial name
- NCT07917910
- Testing
- HT-101 + HT-102
- Volunteers
- 120 people
- Sponsor
- Suzhou HepaThera Biotech Co., Ltd.
Chronic Hepatitis B Infection
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection.
- Trial name
- B-SUPREME (NCT06963710)
- Testing
- ALG-000184, TDF
- Where
- 41 sites in United States, Bulgaria and 12 more
- Volunteers
- 200 people
- Sponsor
- Aligos Therapeutics
Chronic Hepatitis B
Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B
A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131/GST-HG141 tablets in patients with chronic hepatitis B
- Trial name
- NCT07709520
- Testing
- GST-HG141, GST-HG131
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
Chronic Hepatitis B
Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B
This is a phase IV, 2-year, multi-center, single arm and open-label study, evaluating the efficacy and safety with using local manufactured adefovir dipivoxil in Chinese subjects with HBeAg negative chronic hepatitis B
- Trial name
- NCT00324961
- Testing
- adefovir dipivoxil tablets
- Where
- 18 sites in China
- Volunteers
- 533 people
- Sponsor
- GlaxoSmithKline